Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly p...
Main Authors: | Yael Rachamin, Christoph Jakob Ackermann, Oliver Senn, Thomas Grischott |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592494/?tool=EBI |
Similar Items
-
Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
by: PLOS ONE Staff
Published: (2022-01-01) -
Impact of the COVID-19 Pandemic on Elective and Emergency Inpatient Procedure Volumes in Switzerland – A Retrospective Study Based on Insurance Claims Data
by: Yael Rachamin, et al.
Published: (2023-12-01) -
The Impact of COVID-19 on Mental Healthcare Utilization in Switzerland Was Strongest Among Young Females—Retrospective Study in 2018–2020
by: Yael Rachamin, et al.
Published: (2023-05-01) -
Prescription Rates, Polypharmacy and Prescriber Variability in Swiss General Practice—A Cross-Sectional Database Study
by: Yael Rachamin, et al.
Published: (2022-02-01) -
Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
by: Thomas Grischott
Published: (2020-09-01)